Chen A. CD19 And CD22 Dual-Target CAR-T Therapy Via CRISPR/Cas9 Engineering for Relapsed B-Cell Acute Lymphoblastic Leukemia. AJST [Internet]. 2025 Dec. 28 [cited 2026 Jul. 7];18(1):621-5. Available from: https://drpress.org/ojs/index.php/ajst/article/view/33145